Eloquest Healthcare announces new 5-yr agreement with Vizient

October 2, 2020  –  Eloquest Healthcare, Inc., announced a new, 5-year MedSurg agreement with Vizient Inc (Irving, TX) that will include Mastisol Liquid Adhesive, Detachol Adhesive Remover and ReliaTect Post-Op Dressing with CHG.

The new agreement allows Vizient members to take advantage of special pricing for these products.

Mastisol, Detachol and ReliaTect represent solutions to reduce the risk of common healthcare-acquired infections (HAIs) and conditions in the acute-care setting like catheter-related blood stream infection (CRBSI), medical adhesive-related skin injury (MARSI) and post-operative surgical site contamination, respectively.

The agreement is effective October 1, 2020.

Eloquest Healthcare, Inc. is a wholly owned subsidiary of Ferndale Pharma Group, Inc.